MOHAMMADREZA ALLAHYARTORKAMAN

Dr. MOHAMMADREZA ALLAHYARTORKAMAN

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2023 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
ZHZahra Abedi Cham Heidari
Zahra Abedi Cham Heidari
PGParizad Ghanbarikondori
Parizad Ghanbarikondori
EMElham Mortazavi Mamaghani
Elham Mortazavi Mamaghani
AHAli Hheidari
Ali Hheidari
ESElham Saberian
Elham Saberian
MAMOHAMMADREZA ALLAHYARTORKAMAN
MOHAMMADREZA ALLAHYARTORKAMAN
Objective: Addressing both the initial treatment response and subsequent paclitaxel resistance is a pivotal concern. Nano drug delivery, an emerging approach, presents a cutting-edge alternative to conventional chemotherapy. Methods: This investigation synthesized PEGylated nanoparticles (NPs) via the Reverse Phase Evaporation technique for liposomal NPs. Characteristics such as zeta potential, size, drug release and polydispersity index (PDI) were subjected to evaluation. Subsequently, cytotoxicity assays were conducted on gastric cancer cells (AGS) following 24 and 48-hour incubation periods. Results: In this study, the liposomal NPs had a zeta potential of -22 mV and a particle size of 285 nm. The Entrapment efficiency was determined as 41% that occurred physically. Additionally, the liposomal NPs demonstrated a high drug retention rate (39% remained after 72 hours), and they exhibited significantly increased cytotoxicity compared to the free drug, confirming their effectiveness as a suitable carrier for paclitaxel during both incubation periods (P<0.05). Conclusion: These findings collectively advocate the potential of liposomal NPs as promising contenders for effective nano-drug application in propelling chemotherapy forward.

9 January 2024 in Asian Pacific Journal of Cancer Biology
Verified
Journal Article
Open access
PDF file
ZPZahra Pirmoradi
Zahra Pirmoradi
KNKasra Nazari
Kasra Nazari
NSNadia Shafiee
Nadia Shafiee
NNNikou Nikoukar
Nikou Nikoukar
SMShima Minoo
Shima Minoo
MAMOHAMMADREZA ALLAHYARTORKAMAN
MOHAMMADREZA ALLAHYARTORKAMAN
Overview: Oral cancer poses a significant global health challenge, with approximately 300,000 new cases reported annually. Human papillomavirus (HPV) has emerged as a major risk factor for the development of oropharyngeal cancer, constituting around 60% of all oral cancer cases. This review aims to present a comprehensive overview of the current relationship between HPV and oral cancer, covering aspects such as epidemiology, clinical features, detection, treatment, and prevention strategies. Methods: A comprehensive literature search was conducted using Web of Science, PubMed, and Scopus databases to identify studies published in English from January 1983 to the present that investigated the association between HPV and oral cancer. Relevant articles were selected based on their applicability to the topic and methodological quality. Results: The literature search yielded 115 studies that met our inclusion criteria. Our analysis revealed that HPV is a common finding in oral cancer, with a pooled prevalence rate of 72.8%. HPV-positive oral cancer is associated with younger age at diagnosis, male gender, lower stage at presentation, and better prognosis compared to HPV-negative tumors. The HPV genotype most commonly detected in oral cancer is HPV-16, followed by HPV-18. Conclusion: HPV significantly contributes to the onset of oropharyngeal cancer, and identifying it early can serve as a valuable indicator for diagnosis and prognosis. More investigation is required to grasp the molecular mechanisms involved in HPV-related oral cancer and to formulate successful prevention and treatment approaches. Immunization against HPV, particularly in young males, shows potential for decreasing the occurrence of oral cancer linked to HPV.

1 November 2023 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
MAMohadeseh Abbasi
Mohadeseh Abbasi
RRReza Reihanisaransari
Reza Reihanisaransari
FPFatemeh Poustchi
Fatemeh Poustchi
AHAli Hheidari
Ali Hheidari
PGParizad Ghanbarikondori
Parizad Ghanbarikondori
MAMOHAMMADREZA ALLAHYARTORKAMAN
MOHAMMADREZA ALLAHYARTORKAMAN
Objective: Cancer poses a significant challenge in modern medicine, standing as the primary cause of death in many countries, second only to cardiovascular diseases. Among the various treatments available, carboplatin, a chemotherapy drug, is employed for specific cancer types, including brain carcinoma. The main objective of this investigation is to enhance the therapeutic efficacy of carboplatin by utilizing niosomal nanocarriers. Methods: We synthesized nanoniosomal carboplatin using the reverse-phase evaporation technique and conducted an assessment of its particle size, zeta potential, and drug-release properties. Subsequently, we evaluated the cytotoxicity of nanoniosomal carboplatin using the C6 rat glioma cell line. Results: Our research revealed that these niosomal nanoparticles possessed a particle size of 290.5±5.5 nm and a zeta potential of -21.7±7.4 mV. The amount of encapsulated drug and drug loading level were found to be 60.2±2.3% and 2.5±1.1%, respectively. Importantly, the cytotoxic impact of these nanoniosomes on the C6 rat glioma cell line exhibited a significant increase compared to the free drug (P<0.05). Conclusion: Based on our discoveries, it is evident that carboplatin niosomal nanocarriers hold potential as an innovative approach to chemotherapy for brain cancer therapy.